

# SHH MEDULLOBLASTOMA GENE PANEL DG 3.00 (9 genes)

Releasedate: 02-12-2020

| Gene    | Agilent V5 covered > 10x | Agilent V5 covered > 20x | TWIST covered > 10x | TWIST covered 20x | Associated Phenotype description and OMIM disease ID   |
|---------|--------------------------|--------------------------|---------------------|-------------------|--|
| BRCA2   | 99,8                     | 98,5                     | 100                 | 100               | {Pancreatic cancer 2}, 613347<br>{Breast cancer, male, susceptibility to}, 114480<br>{Glioblastoma 3}, 613029<br>Wilms tumor, 194070<br>Fanconi anemia, complementation group D1, 605724<br>{Medulloblastoma}, 155255<br>{Prostate cancer}, 176807<br>{Breast-ovarian cancer, familial, 2}, 612555 |
| ELP1    | 99,8                     | 99                       | 100                 | 100               | Dysautonomia, familial, 223900   |
| GPR161  | 100                      | 100                      | 100                 | 100               | No OMIM disease ID   |
| PALB2   | 100                      | 100                      | 100                 | 100               | {Pancreatic cancer, susceptibility to, 3}, 613348<br>Fanconi anemia, complementation group N, 610832<br>{Breast cancer, susceptibility to}, 114480   |
| PTCH1   | 99,2                     | 97,6                     | 99,9                | 99,8              | Basal cell carcinoma, somatic, 605462<br>Basal cell nevus syndrome, 109400<br>Holoprosencephaly 7, 610828  |
| PTCH2   | 99,9                     | 99                       | 100                 | 100               | Basal cell carcinoma, somatic, 605462<br>Basal cell nevus syndrome, 109400<br>Medulloblastoma, somatic, 155255   |
| SMARCB1 | 100                      | 100                      | 100                 | 100               | Rhabdoid tumors, somatic, 609322<br>{Schwannomatosis-1, susceptibility to}, 162091<br>Coffin-Siris syndrome 3, 614608<br>{Rhabdoid tumor predisposition syndrome 1}, 609322  |
| SUFU    | 100                      | 100                      | 100                 | 100               | Basal cell nevus syndrome, 109400<br>Medulloblastoma, desmoplastic, 155255<br>{Meningioma, familial, susceptibility to}, 607174<br>Joubert syndrome 32, 617757   |
| TP53    | 99,9                     | 97,7                     | 91,7                | 91,7              | {Adrenocortical carcinoma, pediatric}, 202300<br>{Glioma susceptibility 1}, 137800   |

|  |  |  |  |   |
|--|--|--|--|---|
|  |  |  |  | {Basal cell carcinoma 7}, 614740<br>Bone marrow failure syndrome 5, 618165<br>{Colorectal cancer}, 114500<br>Nasopharyngeal carcinoma, somatic, 607107<br>Breast cancer, somatic, 114480<br>{Osteosarcoma}, 259500<br>{Choroid plexus papilloma}, 260500<br>Li-Fraumeni syndrome, 151623<br>Hepatocellular carcinoma, somatic, 114550<br>Pancreatic cancer, somatic, 260350 |
|--|--|--|--|---|

*Gene symbols used follow HGNC guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan 43(Database issue):D1079-85.*

*Agilent V5 is the default chemistry, and used for all exome analyses apart from the (in-house) TURBO/RAPID WES route.*

*TWIST is the chemistry used for (in-house) TURBO/RAPID WES analysis.*

*Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x.*

*Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x.*

*Genes with coverage denoting NC are non-DNA coding genes.*

*non-DNA coding genes are covered, but as coverage statistics are based on DNA coding regions, statistics could not be generated.*

*OMIM release used for OMIM disease identifiers and descriptions : November 20th , 2020.*

*This list is accurate for panel version DG 3.0.0*

*Ad 1. "No OMIM Disease ID" signifies a gene without a current OMIM association Ad 2. OMIM phenotype descriptions between {} signify risk factors*

---